ImmuCell Q3 product sales rise 46% to $8 million, preliminary results show
ImmuCell posted preliminary unaudited Q3 2026 sales of $8 million, up 46% from a year earlier. Domestic sales reached $6.9 million, up 29.2% year over year. * Nine-month sales totaled $25.6 million, a 27.8% increase from the prior-year period. Tri-Shield sales rose 51% year over year; Dual-Force increased 36%; function